...
Initial Request Date | Requested action | Requester(s) | Requestees | Comments |
|---|---|---|---|---|
| 17 August 2021 | As noted above | Please post your responses in the Country response table below. Discussion comments can be made as comments. |
...
| Country | Date | Response |
|---|---|---|
| US | 17AUG2021 | If the third dose/booster is different from the initial doses (e.g., different mRNA to account for the variants), this may warrant a new concept in a drug terminology, such as RxNorm. Otherwise, no new concepts should be created. |
| BELGIUM | 23AUG21 | We've added the vaccin concepts to the Belgian national extension, but as far as I know we do not make a (precoördinated) distinction between a first vaccin and a booster. Also, Belgium is following the WHO guidelines a this moment so giving a thirth dose/booster is not recommended at this point in time. |
| Canada | 20210915 | We do not have requirements for creating additional concepts of that type for now. |
| New Zealand | 20211214 | We are introducing an additional vaccine (third dose) for those who are immunocompromised. Having a way of distinguishing this dose from the usual scheduled doses would be useful |
| Member countries without a CMAG rep |
...